Prescription drug coupons: evolution and need for regulation in direct-to-consumer advertising
- PMID: 24120330
- DOI: 10.1016/j.sapharm.2013.08.002
Prescription drug coupons: evolution and need for regulation in direct-to-consumer advertising
Abstract
Pharmaceutical marketing in the United States had undergone a shift from largely exclusively targeting physicians to considerable efforts in targeting patients through various forms of direct-to-consumer advertising ("DTCA"). This includes the use of DTCA in prescription drug coupons ("PDCs"), a new form of DTCA that offers discounts and rebates directly to consumers to lower costs of drug purchasing. Our examination of PDCs reveals that the use and types of PDC programs is expanding and includes promotion of the vast majority of top grossing pharmaceuticals. However, controversy regarding this emerging form of DTCA has given rise to health policy concerns about their overall impact on prescription drug expenditures for consumers, payers, and the health care system, and whether they lead to optimal long-term utilization of pharmaceuticals. In response to these concerns and the growing popularity of PDCs, what we propose here are clearer regulation and regulatory guidance for PDC DTCA use. This would include review for appropriate disclosure of marketing claims, increased transparency in PDC use for pharmaceutical pricing, and leveraging potential positive benefits of PDC use for vulnerable or underserved patient populations.
Keywords: Direct to consumer advertising; Drug coupons; Drug expenditures; Health law; Health policy.
Copyright © 2014 Elsevier Inc. All rights reserved.
Similar articles
-
It's time to shine the light on direct-to-consumer advertising.Ann Fam Med. 2015 Jan-Feb;13(1):82-5. doi: 10.1370/afm.1711. Ann Fam Med. 2015. PMID: 25583897 Free PMC article.
-
Introduction of direct-to-consumer advertising of prescription drugs in Canada: an opinion survey on regulatory policy.Res Social Adm Pharm. 2005 Jun;1(2):310-30. doi: 10.1016/j.sapharm.2005.03.007. Res Social Adm Pharm. 2005. PMID: 17138480
-
The rise of digital direct-to-consumer advertising?: Comparison of direct-to-consumer advertising expenditure trends from publicly available data sources and global policy implications.BMC Health Serv Res. 2015 Jun 19;15:236. doi: 10.1186/s12913-015-0885-1. BMC Health Serv Res. 2015. PMID: 26084705 Free PMC article.
-
Direct marketing of pharmaceuticals to consumers.Annu Rev Public Health. 2002;23:73-91. doi: 10.1146/annurev.publhealth.23.100901.140537. Epub 2001 Oct 25. Annu Rev Public Health. 2002. PMID: 11910055 Review.
-
The cost-effectiveness of direct-to-consumer advertising for prescription drugs.Med Care Res Rev. 2009 Dec;66(6):639-57. doi: 10.1177/1077558709335362. Epub 2009 May 7. Med Care Res Rev. 2009. PMID: 19423875 Review.
Cited by 4 articles
-
Branded prescription drug spending: a framework to evaluate policy options.J Pharm Policy Pract. 2017 Oct 2;10:31. doi: 10.1186/s40545-017-0115-9. eCollection 2017. J Pharm Policy Pract. 2017. PMID: 29026611 Free PMC article.
-
Fair Balance and Adequate Provision in Direct-to-Consumer Prescription Drug Online Banner Advertisements: A Content Analysis.J Med Internet Res. 2016 Feb 18;18(2):e33. doi: 10.2196/jmir.5182. J Med Internet Res. 2016. PMID: 26892749 Free PMC article.
-
It's time to shine the light on direct-to-consumer advertising.Ann Fam Med. 2015 Jan-Feb;13(1):82-5. doi: 10.1370/afm.1711. Ann Fam Med. 2015. PMID: 25583897 Free PMC article.
-
Privacy in the digital world: medical and health data outside of HIPAA protections.Curr Psychiatry Rep. 2014 Nov;16(11):494. doi: 10.1007/s11920-014-0494-4. Curr Psychiatry Rep. 2014. PMID: 25218603 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
